EXTH-56. MEDULLOBLASTOMAS RESPOND TO CDK4/6 INHIBITION WITH NANOPARTICLE-DELIVERED PALBOCICLIB WITH ALTERED S-PHASE PROGRESSION

CDK4/6 inhibition is a promising therapy for medulloblastoma, one of the most common malignant pediatric brain tumors. To improve pharmacokinetics, we developed a polyoxazoline nanoparticle-encapsulated formulation of the FDA-approved CDK4/6 inhibitor palbociclib (POx-palbo). We then administered PO...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Dismuke, Taylor, Lim, Chaemin, Gershon, Timothy
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Experimental Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846988/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.387
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller